



CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE WITH
SUFFICIENT POSTAGE AS FIRST-CLASS MAIL IN AN ENVELOPE
ADDRESSED TO: ASSISTANT COMMISSIONER OF PATENTS
WASHINGTON, D.C. 20231, ON DECEMBER 19, 2002

72AA
AGENT/ATTORNEY FOR APPLICANT

DEC. 19, 2002
DATE

TECH CENTER 1600/2900

JAN 03 2003

RECEIVED

Attorney Docket No. B2368C4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Hindley, et al.

Application No.: 08/458,033

Filed: June 1, 1995

For: Novel Compounds

Group No.: 1626

Examiner: Robert Gerstl

Commissioner for Patents

Washington, DC 20231

Information Disclosure Statement

The attached list of citations is being submitted under the provisions of 37 C.F.R. §1.56, §1.97 and §1.98 in order to comply with the duty of disclosure. Their inclusion herein, however, should not be construed as an admission that any particular cited reference is effective prior art or that it discloses or renders obvious any aspect of the claimed invention.

The references cited herein are listed on the enclosed PTO Form 1449 and list of co-pending, commonly owned patent applications. Copies of each reference are enclosed.


Applicants note that co-pending, commonly owned Application No. 10/071,824, listed in the attached form, is a continuation of application No. 09/850,965. US Patent Application Publication No. US-2002-0049240A1, listed in the attached form PTO-1449, is the publication of application No. 09/850,965. In addition, a copy of the claims currently pending in application No. 10/071,824 is attached.

A final Office Action has been mailed in the present application. However, this Information Disclosure Statement is being submitted, along with other documents, in accordance with the transitional procedures under 37 CFR 1.129(a) for examination after final rejection. In accordance with 37 CFR 1.129(a) and

MPEP 706.07(g) (August 2001, p 700-66), this Information Disclosure Statement should be treated as though it has been filed within one of the time periods set forth in 37 CFR 1.97(b). Entry and consideration of this Information Disclosure Statement, without any fee or statement set forth in 37 CFR 1.97(c) or (d), is therefore appropriate.

Should the Commissioner determine that any fees are required to process this paper, authorization is hereby given to charge such fees, and to credit any overpayment, to Deposit Account. 19-2570.

Respectfully submitted,



Loretta J. Henderson
Attorney for Applicants
Registration No. 37,347

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-6897
Facsimile (610) 270-5090
n:\loretta\applications\b's\b2368c4\pto 1449 form.doc

DEC 30 2002

Sheet 1 of 2

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeATTY. DOCKET NO.
B2368C4SERIAL NO.
08/458,033**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT***(Use several sheets if necessary)*APPLICANT
Hindley, et al.FILING DATE
June 1, 1995GROUP
1626RECEIVED
JAN 03 2003
TECH. CENTER 1600/1600**U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	4,197,297	04/08/80	Weinstock			
	4,376,777	03/15/83	Kawamatsu et al.			
	4,725,610	02/16/88	Meguro et al.			
	5,002,953	03/26/91	Hindley			
	5,039,687	08/13/91	Effland et al.			
	5,194,443	03/16/93	Hindley			
	5,232,925	08/03/93	Hindley			
	5,260,445	11/09/93	Hindley			
	5,478,852	12/26/95	Olefsky et al.			
	5,521,201	05/28/96	Hindley et al.			
	5,646,169	07/08/97	Hindley et al.			
	5,741,803	04/21/98	Pool et al.			

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	EP 0 008203A1	02/20/80	EPO				
	EP 0 139421A1	05/02/85	EPO				
	EP 0 139421B1	4/27/88	EPO				
	EP 0 155845A1	09/25/85	EPO				
	EP 0 177353A2	04/09/86	EPO				
	EP 0 177353B1	04/11/90	EPO				
	EP 0 193256A1	09/03/86	EPO				
	EP 0 193256B1	04/05/89	EPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Berge, et al., Journal of Pharmaceutical Sciences, vol. 66, no. 1 (1977), pp. 1-19, "Review Article: Pharmaceutical Salts".
	Bottiger (Editor), Carlson et al., Journal of Internal Medicine, vol. 226, no. 4, October 1989, pp. 271-276, "Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipdaemic subjects treated with nicotinic acid".
EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



RECEIVED

JAN 03 2003

TECH CENTER 1600/2900

Sheet 2 of 2

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. B2368C4	SERIAL NO. 08/458,033
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANT Hindley, et al.	
		FILING DATE June 1, 1995	GROUP 1626

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	5,756,525	05/26/98	Hindley et al.			
	5,910,592	06/08/99	Pool et al.			
	6,288,095	09/11/01	Hindley et al.			
	US-2002-0049240A1	04/25/02	Hindley et al.			

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	EP 0207581A2	01/07/87	EPO				
	EP 0208420A1	01/14/87	EPO				
	EP 0208420B1	09/18/91	EPO				
	EP 0306228A1	03/08/89	EPO				
	EP 0306228B1	11/17/99	EPO				
	EP 0419035A1	03/27/91	EPO				
	GB 2082584A	03/10/82	Great Britian				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Cantello, B.C.C. et al., Bioorganic & Medicinal Chemistry Letters 1994, vol. 4, no. 10, pp. 1181-1184, "The synthesis of BRL 49653 - a novel and potent antihyperglycaemic agent".
	Momose, Y. et al., Chem. Pharm. Bull. 1991, vol. 39, no. 6, 1440-1445, "Studies on Antidiabetic Agents. X. Synthesis and biological activities of pioglitazone and related compounds".
	Sohda, et al., Chem. Pharm. Bull., vol. 30, no. 10, October 1982, pp. 3580-3600, "Studies on Antidiabetic Agents. II. Synthesis of 5-[4-(1-methylcyclohexylmethoxy)-benzyl]thiazolidine-2,4-dione (ADD-3878) and its derivatives".

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

n:\voretta\applications\b's\b2368c4\pto 1449 form.doc

U.S. Department of Commerce
Patent and Trademark Office

ATTY. DOCKET NO.
B2368C4

SERIAL NO.
08/458,033

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

APPLICANT
Hindley, et al.

FILING DATE
June 1, 1995

GROUP 1626	
---------------	--

U.S. COPENDING, COMMONLY OWNED PATENT APPLICATIONS

[illegible]

EXAMINER*

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.